Mitsubishi Gas Chemical (MGC) and Becton, Dickinson and Company (BD), a leading global medical technology company, have entered into an agreement to investigate further development of OXYCAPT™—an innovation from MGC that integrates the best of plastic and glass for plastic syringes. Together, the companies will look into applying the OXYCAPT™ technology to the next generation of prefilled syringes (PFS) for advanced biologic pharmaceuticals. Some pharmaceutical compounds based on technologies such as mRNA, viral vectors, or innovative antibodies may face specific stability or integration-with-device challenges when packaged and administered in glass PFS. Through this partnership, MGC and BD will explore practical solutions for delivering newer biologic compounds.